BR0213402A - Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero - Google Patents
Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìferoInfo
- Publication number
- BR0213402A BR0213402A BR0213402-0A BR0213402A BR0213402A BR 0213402 A BR0213402 A BR 0213402A BR 0213402 A BR0213402 A BR 0213402A BR 0213402 A BR0213402 A BR 0213402A
- Authority
- BR
- Brazil
- Prior art keywords
- mammalian cell
- erythropoietin
- producing
- molecule
- proteinaceous
- Prior art date
Links
- 210000004962 mammalian cell Anatomy 0.000 title abstract 11
- 102000003951 Erythropoietin Human genes 0.000 title abstract 7
- 108090000394 Erythropoietin Proteins 0.000 title abstract 7
- 229940105423 erythropoietin Drugs 0.000 title abstract 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title 5
- 210000004027 cell Anatomy 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000004481 post-translational protein modification Effects 0.000 abstract 5
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
"MéTODOS PARA IDENTIFICAR UMA CéLULA DE MAMìFERO CAPAZ DE PRODUZIR UMA MOLéCULA PROTEINáCEA, PARA SELECIONAR UMA CéLULA DE MAMìFERO CAPAZ DE PRODUZIR UMA MOLéCULA PROTEINáCEA, PARA SE OBTER UMA CéLULA DE MAMìFERO A PARTIR DE UMA POPULAçãO HETEROGêNEA DE CéLULAS, E PARA PRODUZIR UMA MOLéCULA PROTEINáCEA, COMPOSIçãO FARMACEUTICAMENTE ACEITáVEL, ERITROPOIETINA RECOMBINANTEMENTE PRODUZIDA, USOS DE UMA CéLULA DE MAMìFERO, DA ERITROPOIETINA RECOMBINANTEMENTE PRODUZIDA, E DE UMA COMPOSIçãO DE MOLéCULAS SEMELHANTES A ERITROPOIETINA, PREPARAçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO PREVENTIVO E/OU TERAPêUTICO DE UM DISTúRBIO COMPOSIçãO DE MOLéCULAS SEMELHANTES à ERITROPOIETINA, MéTODOS PARA PRODUZIR, EM UMA CéLULA DE MAMìFERO, MOLéCULAS PROTEINáCEAS, PARA PRODUZIR UMA FRAçãO ENRIQUECIDA EM UMA MOLéCULA PROTEINáCEA, E PARA FRACIONAR UMA MISTURA QUE CONTEM MOLéCULAS PROTEINáCEAS, FRAçãO, E, USOS DE UMA FRAçãO OU COMPOSIçãO, E DE ERITROPOIETINA RECOMBINANTEMENTE PRODUZìVEL EM UMA CéLULA DE MAMìFERO". A presente invenção provê métodos para identificar, selecionar e obter células de mamíferos que sejam capazes de produzir moléculas proteináceas que compreendem modificações pós-translacionais predeterminadas, em que referidas modificações pós-translacionais são realizadas pela célula de mamífero em que a molécula proteinácea é expressa. Preferivelmente, referidas modificações pós-translacionais prederminadas compreendem glicosilação. A invenção ainda provê métodos para se obter e produzir moléculas proteináceas com o uso de células de mamíferos obteníveis por um método da presente invenção. Preferivelmente, referidas moléculas proteináceas compreendem eritropoietina (EPO), uma vez que o efeito da EPO (recombinante) depende intensamente do padrão de glicosilação dos oligossacarídeos presentes na proteína. As células de mamíferos que foram obtidas à base de sua capacidade de produzir proteínas e/ou modificações pós-translacionais, que são indicativos para uma modificação pós-translacional predeterminada, o que é desejável, são também providas. Preferivelmente, referidas células de mamíferos possuem características neurais e propriedades tais, que quantidades significativas de proteinas recombinantes podem ser produzidas, as quais abriguem propriedades do tipo <39>neural ou cerebral<39>.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2001/000792 WO2003050286A1 (en) | 2001-10-29 | 2001-10-29 | Methods and means for producing proteins with predetermined post-translational modifications |
| PCT/NL2002/000257 WO2003089468A1 (en) | 2002-04-19 | 2002-04-19 | Methods and means for producing proteins with predetermined post-translational modifications |
| PCT/NL2002/000686 WO2003038100A1 (en) | 2001-10-29 | 2002-10-29 | Methods and means for producing proteins with predetermined post-translational modifications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213402A true BR0213402A (pt) | 2004-10-13 |
Family
ID=26642018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213402-0A BR0213402A (pt) | 2001-10-29 | 2002-10-29 | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7304031B2 (pt) |
| EP (2) | EP2292770B1 (pt) |
| JP (1) | JP4583029B2 (pt) |
| CN (1) | CN100347306C (pt) |
| AT (1) | ATE542904T1 (pt) |
| AU (1) | AU2002335585B2 (pt) |
| BR (1) | BR0213402A (pt) |
| CA (2) | CA2465007C (pt) |
| DK (1) | DK1440157T3 (pt) |
| EA (2) | EA008220B1 (pt) |
| ES (1) | ES2381104T3 (pt) |
| IL (3) | IL161674A (pt) |
| NO (1) | NO20042209L (pt) |
| WO (1) | WO2003038100A1 (pt) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| EA008220B1 (ru) * | 2001-10-29 | 2007-04-27 | Круселл Холланд Б.В. | Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения |
| ATE384785T1 (de) | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
| US8524477B2 (en) | 2002-10-29 | 2013-09-03 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
| WO2005090390A1 (en) * | 2004-03-17 | 2005-09-29 | Crucell Holland B.V. | Novel assay for the separation and quantification of hemagglutinin antigens |
| CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| CN101247822B (zh) * | 2005-06-01 | 2012-10-17 | 新潟Tlo株式会社 | 含有epo衍生物的血液相关疾病的治疗剂 |
| AR053416A1 (es) * | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| EP1954815B1 (en) * | 2005-11-15 | 2015-02-25 | GlycoFi, Inc. | Production of glycoproteins with reduced o-glycosylation |
| US7642078B2 (en) | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US7553941B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| CN101460188B (zh) | 2006-06-07 | 2013-09-04 | 国立大学法人德岛大学 | 使用促红细胞生成素的局部缺血疾病的治疗 |
| EP2057997A4 (en) | 2006-08-22 | 2012-11-07 | Chugai Pharmaceutical Co Ltd | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY |
| AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| ES2626080T3 (es) | 2007-04-16 | 2017-07-21 | Momenta Pharmaceuticals, Inc. | Caracterización de N-glicanos utilizando exoglicosidasas |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| US8138092B2 (en) | 2009-01-09 | 2012-03-20 | Lam Research Corporation | Spacer formation for array double patterning |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI532495B (zh) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| CA3163525A1 (en) | 2011-03-31 | 2012-10-04 | Ferring Bv. | Pharmaceutical preparation |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| EP2773964A4 (en) * | 2011-11-03 | 2015-06-24 | Stc Biolog Inc | METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| SG11201503879QA (en) | 2012-11-20 | 2015-06-29 | Opko Biolog Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| CA2954066A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| KR102527180B1 (ko) | 2014-12-10 | 2023-04-27 | 옵코 바이오로직스 리미티드 | 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법 |
| KR102662956B1 (ko) | 2015-06-19 | 2024-05-03 | 옵코 바이오로직스 리미티드 | 장기-작용성 응고 인자 및 그의 제조 방법 |
| EP4303228B1 (en) | 2016-07-11 | 2026-05-27 | OPKO Biologics Ltd. | Long-acting coagulation factor vii and methods of producing same |
| WO2018011302A1 (en) * | 2016-07-12 | 2018-01-18 | Hexal Ag | Glycoprotein with reduced acetylation rate of sialic acid residues |
| US11124579B2 (en) * | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| WO2019075053A1 (en) * | 2017-10-11 | 2019-04-18 | Elanco Us Inc. | PORCINE G-CSF VARIANTS AND USES THEREOF |
| CN116440252A (zh) * | 2020-06-16 | 2023-07-18 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 神经营养因子3在制备提高睾丸中睾酮含量的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| ATE290091T1 (de) * | 1997-03-27 | 2005-03-15 | Univ British Columbia | Insekten-expressionsvektoren |
| CA2221819A1 (en) * | 1997-03-27 | 1998-09-27 | Thomas A. Gigliatti | Insect expression vectors |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| ES2378272T3 (es) * | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| FI109811B (fi) * | 2000-09-26 | 2002-10-15 | Medicel Oy | Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä |
| DE10056136A1 (de) | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| EA008220B1 (ru) | 2001-10-29 | 2007-04-27 | Круселл Холланд Б.В. | Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| WO2005090390A1 (en) | 2004-03-17 | 2005-09-29 | Crucell Holland B.V. | Novel assay for the separation and quantification of hemagglutinin antigens |
| US7183371B2 (en) * | 2004-11-01 | 2007-02-27 | General Electric Company | Method for making polycarbonate |
| US20080139608A1 (en) | 2006-12-06 | 2008-06-12 | Universiteit Leiden | 2,6,8, Trisubstituted 1-deazapurines and their different uses |
-
2002
- 2002-10-29 EA EA200400605A patent/EA008220B1/ru not_active IP Right Cessation
- 2002-10-29 CA CA2465007A patent/CA2465007C/en not_active Expired - Fee Related
- 2002-10-29 EP EP10177590.6A patent/EP2292770B1/en not_active Expired - Lifetime
- 2002-10-29 DK DK02770322.2T patent/DK1440157T3/da active
- 2002-10-29 EA EA200602163A patent/EA012340B1/ru not_active IP Right Cessation
- 2002-10-29 WO PCT/NL2002/000686 patent/WO2003038100A1/en not_active Ceased
- 2002-10-29 CN CNB028216903A patent/CN100347306C/zh not_active Expired - Fee Related
- 2002-10-29 BR BR0213402-0A patent/BR0213402A/pt not_active IP Right Cessation
- 2002-10-29 CA CA2756610A patent/CA2756610C/en not_active Expired - Fee Related
- 2002-10-29 US US10/494,140 patent/US7304031B2/en not_active Expired - Fee Related
- 2002-10-29 EP EP02770322A patent/EP1440157B1/en not_active Expired - Lifetime
- 2002-10-29 JP JP2003540365A patent/JP4583029B2/ja not_active Expired - Fee Related
- 2002-10-29 AU AU2002335585A patent/AU2002335585B2/en not_active Ceased
- 2002-10-29 ES ES02770322T patent/ES2381104T3/es not_active Expired - Lifetime
- 2002-10-29 AT AT02770322T patent/ATE542904T1/de active
-
2004
- 2004-04-29 IL IL161674A patent/IL161674A/en not_active IP Right Cessation
- 2004-05-28 NO NO20042209A patent/NO20042209L/no not_active Application Discontinuation
-
2007
- 2007-01-24 US US11/657,202 patent/US7785833B2/en not_active Expired - Fee Related
- 2007-08-01 US US11/888,776 patent/US7696157B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 IL IL201674A patent/IL201674A/en not_active IP Right Cessation
- 2009-10-21 IL IL201673A patent/IL201673A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2465007C (en) | 2012-01-17 |
| CN100347306C (zh) | 2007-11-07 |
| IL161674A (en) | 2014-06-30 |
| JP2005507426A (ja) | 2005-03-17 |
| EA008220B1 (ru) | 2007-04-27 |
| US7785833B2 (en) | 2010-08-31 |
| CA2465007A1 (en) | 2003-05-08 |
| CN1578838A (zh) | 2005-02-09 |
| US7304031B2 (en) | 2007-12-04 |
| ATE542904T1 (de) | 2012-02-15 |
| NO20042209L (no) | 2004-07-28 |
| ES2381104T3 (es) | 2012-05-23 |
| US7696157B2 (en) | 2010-04-13 |
| EP2292770A3 (en) | 2012-12-19 |
| IL201674A (en) | 2013-10-31 |
| EA200602163A1 (ru) | 2007-04-27 |
| WO2003038100A1 (en) | 2003-05-08 |
| IL201673A (en) | 2013-10-31 |
| EA200400605A1 (ru) | 2004-08-26 |
| EP1440157B1 (en) | 2012-01-25 |
| DK1440157T3 (da) | 2012-05-07 |
| US20050164917A1 (en) | 2005-07-28 |
| CA2756610A1 (en) | 2003-05-08 |
| EP1440157A1 (en) | 2004-07-28 |
| CA2756610C (en) | 2015-08-25 |
| AU2002335585B2 (en) | 2007-08-16 |
| EP2292770A2 (en) | 2011-03-09 |
| EA012340B1 (ru) | 2009-10-30 |
| US20070117742A1 (en) | 2007-05-24 |
| EP2292770B1 (en) | 2014-11-26 |
| US20080032922A1 (en) | 2008-02-07 |
| JP4583029B2 (ja) | 2010-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL201673A (en) | A method for producing a portion of protein molecules enriched with glycans in n | |
| Fahnestock et al. | ProNGF: a neurotrophic or an apoptotic molecule? | |
| EP2277888A3 (en) | Fusion proteins of albumin and erythropoietin | |
| BRPI0109494B8 (pt) | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii | |
| NZ223506A (en) | Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions | |
| ATE258984T1 (de) | Bmp-11 zusammensetzungen | |
| KR900700116A (ko) | 뼈-유도 단백질 | |
| BR0207325A (pt) | Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1 | |
| KR960703433A (ko) | 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity) | |
| BR0208207A (pt) | Redução da imunogenicidade das proteìnas de fusão | |
| DE69029657D1 (de) | Menschliches cytokin, interleukin-9 | |
| Nilsen-Hamilton et al. | Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH | |
| EP1420031A3 (en) | Bone morphogenetic protein (BMP)-18 compositions | |
| DE60027409D1 (de) | Glykosylierte leptinzusammensetzungen und zugehörige verfahren | |
| DE69101634D1 (de) | Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. | |
| PT1028744E (pt) | Utilizcoes neuronais de bmp-11 | |
| LV11803A (lv) | Nesplaisinga gp350/220 varianti | |
| ATE331032T1 (de) | Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung | |
| Guisasola et al. | Plasmin digestion of factor VIII: characterization of the breakdown products with respect to antigenicity and von Willebrand activity | |
| ATE302214T1 (de) | Enamel-matrix bezogene polypeptide | |
| ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
| DE69018659D1 (de) | 3- oder 4-substituierte Oxotremorin-Derivate. | |
| BR9004693A (pt) | Solucao aquosa,processo para aumentar a concentracao de proteina de uma proteina em uma solucao aquosa,e composicao farmaceutica | |
| TAKAGI et al. | Characterization of “abp38” in cytoskeleton of mouse myeloid leukemia cells and distribution of abp38 in various tissues | |
| DE60237983D1 (de) | Von menschlichen und säugerstammzellen abgeleitete neuronale überlebenspolypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |